vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.69M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Spruce Biosciences, Inc. NASDAQ:SPRB | $124.47M | $43.31 | Not rated | -1.9 | -60.54% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -78.67% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $94.82M | $2.19 | Not rated | -5.3 | +25.62% |
Fortress Biotech, Inc. NASDAQ:FBIO | $62.70M | $1.88 | Undervalued | 0.7 | -30.04% |
MiNK Therapeutics, Inc. NASDAQ:INKT | $47.66M | $9.34 | Not rated | -4.6 | -6.03% |
Werewolf Therapeutics, Inc. NASDAQ:HOWL | $47.64M | $0.98 | Not rated | -1.4 | +20.51% |
Gain Therapeutics, Inc. NASDAQ:GANX | $44.36M | $1.04 | Not rated | -3.6 | -58.60% |
OS Therapies Incorporated AMEX:OSTX | $34.87M | $0.75 | Not rated | -2.0 | -29.01% |
Continue the stock analysis
Jump to another research area for this company.